The independent Data and Safety Monitoring Board on Thursday unanimously approved Clearmind Medicine Inc.
(NASDAQ:CMND) to advance its ongoing FDA-regulated Phase 1/2 clinical trial.
The study evaluates CMND-100, a clinical candidate aimed at treating Alcohol Use Disorder (AUD), in Parts B and C of the trial.
The progression follows the successful conclusion of Part A.
In that initial phase, CMND-100 achieved its primary safety endpoint, displaying a positive safety and tolerability profile across all planned dose levels in healthy individuals.
